Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

Fact checked by Jennifer Klump The first “biological missile" drug that was approved to treat breast cancer just got a step ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Daiichi Sankyo has a leading ADC platform, a cutting-edge modality for cancer treatments that improves upon the safety and efficacy of existing chemotherapy treatments. Enhertu has demonstrated ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

Enhertu is an antibody drug conjugate (ADC) that was discovered by Daiichi Sankyo and is being further developed and commercialized under a partnership with AstraZeneca. The antibody component of ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with ...

Daiichi Sankyo reported full-year revenue of JPY 1,886 ... Datroway's Avanzar trial in first-line non-small-cell lung cancer and Enhertu's Destiny-Breast05 and Destiny-Breast11 trials in early ...